Disufenton Sodium had been in phase III clinical trials for the treatment of stroke. This compound was originally discovered by Renovis (acquired by Evotec in 2008), then licensed and developed by AstraZeneca in collaboration with Otologic Pharmaceutics. However, this study was discontinued.
Update Date:2016-02-24
Update Date:2015-12-08
Update Date:2016-04-08